Concepedia

Naval Daver

ND

Statistics

Publications

399

Citations

23.3K

H-Index

78

Active since

2005

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Dana-Farber Cancer Institute

University of California, Irvine

Moffitt Cancer Center

Roswell Park Comprehensive Cancer Center

Naval Daver is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, hematologic malignancy therapy, and oncology.

ORCID

Publications per year

2005–2025

399

Publications

399

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Jennifer R. Molina, Yuting Sun, Marina Protopopova et al. · Nature Medicine · 2018 · 951 citations · Full text

, , +14

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

Naval Daver, Guillermo Garcia‐Manero, Sreyashi Basu et al. · Cancer Discovery · 2018 · 571 citations

, , +17

Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

Courtney D. DiNardo, Caitlin R. Rausch, Christopher B. Benton et al. · American Journal of Hematology · 2017 · 437 citations · Full text

, , +17

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

Farhad Ravandi, Mona Lisa Alattar, Michael R. Grunwald et al. · Blood · 2013 · 378 citations

, , +12

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Timothy A. Yap, Naval Daver, Mikhila Mahendra et al. · Nature Medicine · 2023 · 377 citations

, , +14

1–5 of 399